Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin plus docetaxel for EGFR-TKI-resistant non-small cell lung cancer
ChiCTR-ONC-09000355Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar and docetaxel in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Response rate, Progression-free survival and 1 more. Started Apr 2009; status: completed.
02
Drugs
endostardocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-ONC-09000355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-09000355.